Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

RATIONALE: Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works as first-line therapy in treating patients with locally advanced or metastatic papillary …

carcinoma
neutrophil count
sunitinib
measurable disease
progressive disease
  • 27 views
  • 07 Nov, 2020
  • 13 locations
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

The goal of this clinical research study is to compare the safety and effectiveness of cabozantinib and sunitinib when given to patients with metastatic (has spread) variant histology renal cell carcinoma (vhRCC), a type of kidney cancer. This is an investigational study. Cabozantinib and sunitinib are both FDA approved and …

cabozantinib
everolimus
vascular endothelial growth factor
ipilimumab
carcinoma
  • 7 views
  • 17 Jan, 2021
  • 4 locations
Combination of Temozolomide and Sunitinib in Treatment of Patients With Metastatic and Unresectable Malignant Melanoma

, sunitinib malate in patients with advanced melanoma..

advanced melanoma
temozolomide
  • 23 views
  • 07 Nov, 2020
  • 1 location
Sunitinib Tamoxifen and Cisplatin in Treating Patients With High-Risk Ocular Melanoma

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as tamoxifen and cisplatin, work in different ways to stop the growth of tumor cells, either by killing …

tumor cells
  • 19 views
  • 07 Nov, 2020
  • 1 location
Sunitinib in Treating Patients With Recurrent or Unresectable Meningioma Intracranial Hemangiopericytoma or Intracranial Hemangioblastoma

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying sunitinib to see how well it works in treating patients with recurrent or unresectable meningioma, intracranial hemangiopericytoma, or intracranial hemangioblastoma.

  • 86 views
  • 07 Nov, 2020
  • 1 location